Horizon Pharma plc HZNP is a biopharmaceutical company focused on identifying, developing, acquiring and commercializing products addressing the unmet therapeutic needs in arthritis, pain, inflammatory and orphan diseases.
This Dublin, Ireland-based company has seven marketed products. Key products include Actimmune (chronic granulomatous disease and severe malignant osteopetrosis), Duexis (signs and symptoms of osteoarthritis and rheumatoid arthritis (RA)), Pennsaid (pain of osteoarthritis of the knee) and Vimovo (signs and symptoms of osteoarthritis, RA and ankylosing spondylitis).
Horizon Pharma has posted a positive earnings surprise in two of the trailing four quarters, with an average negative earnings surprise of ArrayArray.34%.
Currently, Horizon Pharma has a Zacks Rank #Array (Strong Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Horizon Pharma failed to beat on earnings. Our consensus called for EPS of 65 cents, and the company reported EPS of 45 cents (these figures include stock-based compensation expense).
Revenue: Revenues were, however, above expectations. Horizon Pharma posted revenues of $244.5 million, compared to our consensus estimate of $243 million.
Key Stats: The company’s key products, Duexis, Rayos and Actimmune performed well during the quarter. The addition of Ravicti and Buphenyl is a huge boost to the company. The company provided its 20Array6 net sales guidance. The company expects 20Array6 net sales to be around $Array.02 to $Array.05 billion.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment